Citizens Reiterates Market Outperform on Taysha Gene Therapies (TSHA), Sees Edge in Rett Therapy
Tweet Send to a Friend
Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $6.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
